Trevi Therapeutics Unveils Detailed Phase 3 Plans, Reports Cash Runway into 2028
summarizeSummary
Trevi Therapeutics announced strong financial results, ending 2025 with $188.3 million in cash, cash equivalents, and marketable securities, providing an expected cash runway into 2028. This significant liquidity provides a solid foundation for its ambitious clinical programs. The company also provided detailed business updates, including the specific plans for its pivotal Phase 3 program for IPF-related chronic cough, which involves two parallel trials initiating in Q2 and H2 2026. This follows the successful End-of-Phase 2 meeting with the FDA announced earlier this month, with these details providing critical clarity on the development path. Additionally, Trevi plans to initiate Phase 2b trials for refractory chronic cough and non-IPF ILD-related chronic cough in 2026. These updates de-risk the company's pipeline and provide a clear path forward for its lead candidate, making the stock highly attractive to traders. Investors will now watch for the initiation of these pivotal trials.
At the time of this announcement, TRVI was trading at $10.88 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $4.85 to $14.39. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.